JP2024522388A5 - - Google Patents

Info

Publication number
JP2024522388A5
JP2024522388A5 JP2023566659A JP2023566659A JP2024522388A5 JP 2024522388 A5 JP2024522388 A5 JP 2024522388A5 JP 2023566659 A JP2023566659 A JP 2023566659A JP 2023566659 A JP2023566659 A JP 2023566659A JP 2024522388 A5 JP2024522388 A5 JP 2024522388A5
Authority
JP
Japan
Prior art keywords
atoms
linear
alkoxy
alkyl
pharmaceutically acceptable
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023566659A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024522388A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/CN2022/089725 external-priority patent/WO2022228494A1/zh
Publication of JP2024522388A publication Critical patent/JP2024522388A/ja
Publication of JP2024522388A5 publication Critical patent/JP2024522388A5/ja
Pending legal-status Critical Current

Links

JP2023566659A 2021-04-29 2022-04-28 抗体薬物複合体の調製方法および使用 Pending JP2024522388A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN202110475315 2021-04-29
CN202110475315.1 2021-04-29
PCT/CN2022/089725 WO2022228494A1 (zh) 2021-04-29 2022-04-28 抗体偶联药物的制备方法及应用

Publications (2)

Publication Number Publication Date
JP2024522388A JP2024522388A (ja) 2024-06-19
JP2024522388A5 true JP2024522388A5 (enExample) 2025-03-31

Family

ID=83846703

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2023566659A Pending JP2024522388A (ja) 2021-04-29 2022-04-28 抗体薬物複合体の調製方法および使用
JP2023566660A Pending JP2024522389A (ja) 2021-04-29 2022-04-28 抗体薬物複合体の調製方法および使用
JP2023566547A Pending JP2024522312A (ja) 2021-04-29 2022-04-28 抗体薬物複合体の調製方法および使用

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2023566660A Pending JP2024522389A (ja) 2021-04-29 2022-04-28 抗体薬物複合体の調製方法および使用
JP2023566547A Pending JP2024522312A (ja) 2021-04-29 2022-04-28 抗体薬物複合体の調製方法および使用

Country Status (10)

Country Link
US (3) US20240245795A1 (enExample)
EP (3) EP4331613A1 (enExample)
JP (3) JP2024522388A (enExample)
KR (2) KR20240006028A (enExample)
CN (3) CN117241834A (enExample)
AU (1) AU2022263700A1 (enExample)
CA (3) CA3173511A1 (enExample)
IL (1) IL308025A (enExample)
TW (3) TW202308700A (enExample)
WO (3) WO2022228494A1 (enExample)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW202308700A (zh) * 2021-04-29 2023-03-01 大陸商上海匯連生物醫藥有限公司 抗體偶聯藥物的製備方法及應用
WO2024083162A1 (en) 2022-10-19 2024-04-25 Multitude Therapeutics Inc. Antibodies, antibody-drug conjugates, preparations and uses thereof
WO2024091437A1 (en) * 2022-10-25 2024-05-02 Merck Sharp & Dohme Llc Exatecan-derived adc linker-payloads, pharmaceutical compositions, and uses thereof
WO2024149345A1 (en) * 2023-01-11 2024-07-18 Profoundbio Us Co. Linkers, drug linkers and conjugates thereof and methods of using the same
WO2024193692A1 (zh) * 2023-03-22 2024-09-26 映恩生物制药（苏州）有限公司 连接子及其在配体药物偶联物中的应用
TW202438069A (zh) * 2023-03-30 2024-10-01 大陸商上海齊魯製藥研究中心有限公司 依喜替康衍生物及其抗體藥物偶聯物
WO2024212922A1 (zh) * 2023-04-11 2024-10-17 映恩生物制药（苏州）有限公司 喜树碱类化合物及其偶联物、其制备方法和用途
CN118852442A (zh) 2023-04-26 2024-10-29 上海麦科思生物医药有限公司 抗ptk7抗体及其用途
WO2024230678A1 (zh) * 2023-05-11 2024-11-14 映恩生物科技(上海)有限公司 喜树碱类化合物及其偶联物、其制备方法和用途
AU2024274983A1 (en) * 2023-05-19 2025-11-20 Solve Therapeutics, Inc. Drug-linkers and drug conjugates
WO2024250984A1 (zh) * 2023-06-07 2024-12-12 上海维申医药有限公司 一种抗体药物偶联物，及其药物组合物、制备和用途
EP4737483A1 (en) * 2023-06-30 2026-05-06 Daiichi Sankyo Company, Limited Antibody-drug conjugate production method including purification step using activated carbon material
AU2024288808A1 (en) 2023-07-07 2026-01-22 Shanghai Escugen Biotechnology Co., Ltd. Linker-drug molecule and antibody drug conjugate, preparation method therefor and use thereof
AU2024319420A1 (en) * 2023-08-04 2026-03-19 Shanghai Huao Co., Ltd. Multidrug linker and antibody-drug conjugate
WO2025064733A1 (en) * 2023-09-22 2025-03-27 Obi Pharma, Inc. Improved linker-payloads for antibody conjugation, pharmaceutical compositions and applications thereof
TW202525860A (zh) * 2023-10-23 2025-07-01 大陸商上海齊魯製藥研究中心有限公司 喜樹鹼類藥物耦合物及其製備方法和應用
EP4566631A1 (en) * 2023-12-06 2025-06-11 Heidelberg Pharma Research GmbH New antibody drug conjugate as well as methods of production and uses thereof
WO2025149019A1 (en) * 2024-01-12 2025-07-17 Shanghai Ruotuo Biosciences Co., Ltd. Antibody-drug conjugates, pharmaceutical compositions, and therapeutic applications
WO2025153092A1 (en) * 2024-01-18 2025-07-24 Beijing Joinn Biologics Co., Ltd Antibody-drug conjugate
WO2025171055A1 (en) 2024-02-06 2025-08-14 Kumquat Biosciences Inc. Heterocyclic conjugates and uses thereof
WO2025209545A1 (zh) * 2024-04-03 2025-10-09 上海药明合联生物技术有限公司 用于抗体药物偶联物的连接子、其用途和由其制备的抗体药物偶联物
WO2025222052A2 (en) * 2024-04-18 2025-10-23 Solve Therapeutics, Inc. Conjugates and uses thereof
WO2025259928A1 (en) * 2024-06-13 2025-12-18 Obi Pharma, Inc. Improved trop2 conjugated biological molecules, pharmaceutical compositions and applications thereof
WO2025261478A1 (en) * 2024-06-21 2025-12-26 Biotheus Inc. Antibody drug conjugates and applications thereof
US20260048137A1 (en) 2024-08-16 2026-02-19 Ardeagen Corporation Anti-mesothelin antibody conjugates and methods of use thereof
WO2026037394A1 (zh) * 2024-08-16 2026-02-19 石药集团巨石生物制药有限公司 一种抗体药物偶联物及其用途
WO2026046186A1 (en) * 2024-08-27 2026-03-05 Suzhou Bioreinno Biotechnology Limited Company Linkers, linker conjugates and conjugate compounds thereof
WO2026067624A1 (zh) * 2024-09-27 2026-04-02 上海森辉医药有限公司 一种包含亲水基团的配体-药物偶联物及其在医药上的应用
CN119143876B (zh) * 2024-10-09 2025-09-16 武汉海沙百得生物技术有限公司 一种抗cd27l的全人源抗体或抗体片段及其应用
WO2026078443A1 (en) 2024-10-11 2026-04-16 Pheon Therapeutics Ltd. Antibody drug conjugates that bind cdcp1 and uses thereof
CN120484249B (zh) * 2025-04-29 2026-03-10 中山大学 一种含氟修饰的聚肌氨酸化脂质及其制备方法和应用

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5391745A (en) * 1992-07-23 1995-02-21 Sloan-Kettering Institute For Cancer Research Methods of preparation of camptothecin analogs
WO2003041660A2 (en) * 2001-11-14 2003-05-22 Rutgers, The State University Solubilized topoisomerase poisons
CA2478047C (en) 2002-03-01 2014-01-21 Immunomedics, Inc. Rs7 antibodies
JP2006316040A (ja) 2005-05-13 2006-11-24 Genentech Inc Ｈｅｒｃｅｐｔｉｎ（登録商標）補助療法
AR056857A1 (es) 2005-12-30 2007-10-24 U3 Pharma Ag Anticuerpos dirigidos hacia her-3 (receptor del factor de crecimiento epidérmico humano-3) y sus usos
US9089614B2 (en) * 2012-12-21 2015-07-28 Bioalliance C.V. Hydrophilic self-immolative linkers and conjugates thereof
MX368259B (es) 2013-04-16 2019-09-25 Genentech Inc Variantes de pertuzumab y su evaluacion.
CN105722851A (zh) * 2013-04-28 2016-06-29 秦刚 一种新型的连接子及其制备方法和用途
AU2014371934B2 (en) * 2013-12-25 2020-01-23 Daiichi Sankyo Company, Limited Anti-TROP2 antibody-drug conjugate
JP6666264B2 (ja) * 2014-04-29 2020-03-13 ジーンクアンタム ヘルスケア （スーチョウ） シーオー．， エルティーディー．Ｇｅｎｅｑｕａｎｔｕｍ Ｈｅａｌｔｈｃａｒｅ （Ｓｕｚｈｏｕ）Ｃｏ．， Ｌｔｄ． 新規安定型抗体薬物複合体の作製およびその応用
GB201416112D0 (en) 2014-09-12 2014-10-29 Medimmune Ltd Pyrrolobenzodiazepines and conjugates thereof
CN116059395A (zh) 2015-06-29 2023-05-05 第一三共株式会社 用于选择性制造抗体-药物缀合物的方法
EP3347048B1 (en) 2015-09-09 2020-04-01 INSERM (Institut National de la Santé et de la Recherche Médicale) Antibodies having specificity to nectin-4 and uses thereof
CN108066772B (zh) * 2016-11-14 2021-07-13 中国科学院上海药物研究所 靶向tacstd2的抗体与药物偶联体(adc)分子
TW202532104A (zh) 2017-05-15 2025-08-16 日商第一三共股份有限公司 抗體－藥物結合物及其用途
JP7381478B2 (ja) * 2017-10-23 2023-11-15 マブリンク ビオシオンス 単一分子量ポリサルコシンを含むリガンド－薬物－複合体
CA3085001C (en) 2019-05-20 2021-10-05 Mabplex International, Ltd. One-pot process for preparing intermediate of antibody-drug conjugate
CN113853219B (zh) * 2019-05-20 2025-01-07 诺华股份有限公司 具有包含亲水性基团的接头的抗体药物缀合物
TW202308700A (zh) * 2021-04-29 2023-03-01 大陸商上海匯連生物醫藥有限公司 抗體偶聯藥物的製備方法及應用

Similar Documents

Publication Publication Date Title
JP2024522388A5 (enExample)
JP2024522389A5 (enExample)
JP2024522312A5 (enExample)
JP2012522512A5 (enExample)
JP2022511351A5 (enExample)
Elgersma et al. Design, synthesis, and evaluation of linker-duocarmycin payloads: toward selection of HER2-targeting antibody–drug conjugate SYD985
HRP20250345T1 (hr) Konjugati antitijelo - lijek derivata cikličnih dinukleotida
RU2014148162A (ru) Анти-pmel17 антитела и их иммуноконъюгаты
JP2012522513A5 (enExample)
JP2022101693A5 (enExample)
JP2022530524A5 (enExample)
JP2020526584A5 (enExample)
RU2011144119A (ru) АНТИТЕЛА К FcRH5, ИХ ИММУНОКОНЪЮГАТЫ И СПОСОБЫ ИХ ПРИМЕНЕНИЯ
RU2019129839A (ru) Производные майтанзиноида с саморасщепляющимися пептидными линкерами и их конъюгаты
JP2019502650A5 (ja) 抗ＥｒｂＢ２抗体−薬物コンジュゲート及びその組成物、そのための調製方法、並びにその使用
JP2015523961A5 (enExample)
RU2009119976A (ru) Антитела и иммуноконъюгаты и их применение
JP2024540691A5 (enExample)
JP2023509214A5 (enExample)
JP2024545170A5 (enExample)
JP2025527006A (ja) 部位特異的修飾を有する抗体の調製方法
TW202310878A (zh) 艾日布林衍生物的藥物偶聯物
JPWO2023033129A5 (enExample)
RU2025129383A (ru) Конъюгат антитело-лекарственное средство
WO2026092606A1 (zh) 带有连接系统的抗体药物偶联物